Moors & Cabot’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Moors & Cabot’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-56,500	Closed	-$50.1K	–	937
2022 Q4	$50.1K	Sell	56,500 -2,000	-3%	-$2.65K	﹤0.01%	815
2022 Q3	$92K	Sell	58,500 -3,000	-5%	-$6.8K	0.01%	769
2022 Q2	$124K	Sell	61,500 -1,000	-2%	-$1.73K	0.01%	742
2022 Q1	$146K	Buy	62,500 +50,750	+432%	+$158K	0.01%	796
2021 Q4	$55K	Buy	+11,750	New	+$72.9K	﹤0.01%	839
2020 Q4	–	Sell	-17,650	Closed	-$197K	–	788
2020 Q3	$197K	Buy	+17,650	New	+$162K	0.02%	600

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Moors & Cabot's SRNE Position: Q1 2023 in Review

Moors & Cabot sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 56,500 shares — an estimated $50.1K sold.

Moors & Cabot first reported a position in SRNE in Q3 2020 and held it in 6 quarters. The position peaked at $197K in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Moors & Cabot reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Moors & Cabot sold 56,500 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $50.1K.
Moors & Cabot first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 6 quarters.
Moors & Cabot's Sorrento Therapeutics, Inc. position peaked at $197K in Q3 2020.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Moors & Cabot's 13F filing for Q1 2023, filed 5 May 2023.